Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702288 | Practical Radiation Oncology | 2017 | 27 Pages |
Abstract
Postmastectomy IMPT in breast cancer patients with expanders is feasible and associated with favorable clinical target volume coverage and normal tissue sparing, even when taking into account treatment uncertainties; therefore, these patients should be eligible to participate in clinical trials studying the potential role of proton therapy in breast cancer. We caution, however, that institutions should carry out similar analyses of the physical properties and dosimetric impact of the particular expanders used in their practice before considering IMPT.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Robert W. MD, Nicholas B. PhD, Mohamed MH MBBS, Kathy A. BS, Deanna H. PhD, Yan PhD, Kimberly S. MD, Sean S. MD, PhD, Elizabeth S. MD, Valerie MD, Judy C. MD, Chris J. PhD,